PAQ Therapeutics Reveals Promising Phase 1 Data for PT0253 Targeting KRAS G12D in Cancer Treatment

Promising Results for PT0253 in Cancer Treatment



PAQ Therapeutics, a clinical-stage biotechnology company, has recently unveiled encouraging results from its ongoing Phase 1 trial of PT0253, a selective degrader targeting the KRAS G12D mutation prevalent in various advanced cancers. The data, presented at the ENA 2026 symposium in Barcelona, demonstrates a differentiated safety profile and notable antitumor activity.

Context of the Study


In a landscape marked by limited treatment options for patients with KRAS-driven cancers, the trial's findings represent a significant advancement. With approximately 44 patients enrolled, the trial evaluated the safety and efficacy of PT0253 administered intravenously at escalating doses between 10 and 750 mg. Notably, this targeted approach is designed to combat resistance mechanisms frequently observed with existing KRAS inhibitors.

Key Findings


Safety and Tolerability


The trial outcomes reflect a robust safety profile for PT0253. Across all administered doses, no dose-limiting toxicities were reported, which is a significant achievement. Adverse events were predominantly ranked as Grade 1 to 2, with only one case of Grade 3 toxicity reported among participants. Crucially, the absence of serious treatment-related adverse events or the need for special pre-treatment prophylaxis highlights the favorable safety profile of this novel therapy.

Antitumor Activity Observed


The efficacy results from PT0253 monotherapy were equally encouraging. Partial responses to treatment were recorded in patients suffering from various cancer types including colorectal and pancreatic cancers, particularly among those who had previously undergone treatment with KRAS-targeted therapies. Specifically, 50% of patients whose disease progressed on earlier therapies demonstrated disease control, signaling a promising potential for PT0253 in this challenging patient cohort.

Combination Therapy Potential


In an intriguing expansion of the trial, PT0253 was also evaluated in combination with standard-of-care chemotherapy regimen mFOLFIRINOX for first-line metastatic pancreatic cancer cases. Initial data indicated that among patients receiving this combination treatment, an impressive 86% achieved objective responses, highlighting the robustness of PT0253 when paired with conventional therapies.

Expert Perspectives


Dr. Alexander I. Spira from NEXT Oncology, who presented the findings, emphasized the significant implications of the trial results in altering treatment paradigms for KRAS G12D-mutant cancers. According to him, the early activity demonstrated in previously treated patients, coupled with PT0253's tolerability, is a beacon of hope for those encountering limited therapeutic options.

PAQ's Chief Executive Officer, Nan Ji, also expressed optimism regarding these initial results, reinforcing the company's commitment to advancing KRAS degradation strategies as a viable and transformative therapeutic avenue. Dr. Andrew P. Krivoshik, the Chief Medical Officer at PAQ Therapeutics, acknowledged the maintained intensity of chemotherapy doses amongst patients, affirming the compatibility of PT0253 with established treatment regimens.

Conclusion


The data presented at ENA 2026 marks a pivotal step towards understanding the clinical value of PT0253 in managing KRAS G12D-mutant cancers. With ongoing efforts to further analyze these promising findings and expand the study to larger patient cohorts, PAQ Therapeutics is positioning itself as a key player in redefining treatment approaches in oncology, particularly for patients with KRAS-driven malignancies. As the landscape of cancer treatment continues to evolve, the implications of these findings could pave the way for novel therapeutic options and improved outcomes for patients grappling with these aggressive cancers.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.